Article    Table of Contents                    PDF of this article    Related articles in Annals    Articles citing this article  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Leung, N.    Griffin, M. D.    PubMed

REPLY

Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy

Nelson Leung, MD; Sundararaman Swaminathan, MBBS; Iftikhar Ahmed, MD; James T. McCarthy, MD; Robert C. Albright, DO; Mark R. Pittelkow, MD; Noel M. Caplice, MD, PhD; and Matthew D. Griffin, MB BCh

6 February 2007 | Volume 146 Issue 3 | Page 230

---

IN RESPONSE:

We appreciate Dr. Hellman's interest and comments. We, too, have noted that nearly half of our patients with nephrogenic fibrosing dermopathy had gadolinium exposure before the development of their disease. However, a similar number of our 50 dialysis patients were also exposed to gadolinium—some exposed on several occasions—without any evidence of the condition. This seems to support our hypothesis that multiple factors are involved in the pathogenesis of nephrogenic fibrosing dermopathy. We are currently investigating the possible interaction between gadolinium and erythropoietin in this disease.

Author and Article Information

Top Author & Article Info

From Mayo Clinic College of Medicine, Rochester, Minnesota.

Potential Financial Conflicts of Interest: None disclosed.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

Related articles in Annals:

Letters
Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy
Sundararaman Swaminathan, Iftikhar Ahmed, James T. McCarthy, Robert C. Albright, Mark R. Pittelkow, Noel M. Caplice, Matthew D. Griffin, AND Nelson Leung

Annals 2006 145: 234-235. [Full Text]  

Letters
Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy
Richard N. Hellman

Annals 2007 146: 229-230. [Full Text]  

This article has been cited by other articles:

				S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146. [Abstract] [PDF]

				H. Pieringer, S. Schumacher, B. Schmekal, T. Gitter, and G. Biesenbach Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure NDT Plus, June 1, 2008; 1(3): 193 - 194. [Full Text] [PDF]